Physician profile
Saba Memon
NPI 1609030881
$808.42
in general payments reported to CMS, 2019-2025
12 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.83 · 2020: $21.43 · 2021: $214 · 2022: $117 · 2023: $13.69 · 2024: $172 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.50 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $115.15 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $93.12 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $84.13 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $81.21 | 2021-2025 | |
| Corium, LLC | $80.12 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $60.86 | 2021-2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $52.94 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.52 | 2021 | |
| Livanova USA, INC. | $19.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.